Clearmind Medicine Set to Execute 1-for-40 Reverse Stock Split Next Week
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Source: NASDAQ.COM
Reverse Share Split Announcement: Clearmind Medicine Inc. has announced a 1-for-40 reverse share split, effective December 15, 2025, to comply with Nasdaq's Minimum Bid Price Rule, reducing outstanding shares from approximately 59.99 million to 1.50 million.
Clinical Trials Progress: The company's lead drug candidate, CMND-100 (MEAI), is currently in Phase I/IIa clinical testing for alcohol use disorder, with positive early results prompting the continuation of the study.
Additional Research: Clearmind is also developing other psychedelic-derived compounds aimed at treating binge behaviors, depression, and metabolic disorders, which are in preclinical stages.
Stock Performance: CMND's stock has fluctuated between $0.10 and $2.18 over the past year, closing at $0.114 before dropping 23% in premarket trading to $0.08.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like CMND with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on CMND
About CMND
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Clearmind Regains Nasdaq Compliance with Share Price Above $1
- Compliance Restoration: Clearmind Medicine confirmed on December 30, 2025, that its common shares have maintained a closing price above $1 for the last 10 consecutive trading days, successfully regaining compliance with Nasdaq Listing Rule 5550(a)(2), indicating positive progress in stock price stability.
- Price Volatility Context: Previously, Clearmind was notified on December 4, 2025, of non-compliance due to its share price being below $1 for over 30 consecutive trading days, and this compliance restoration is expected to enhance investor confidence and attract more capital inflow.
- Market Reaction Expectations: With the restoration of compliance, Clearmind is likely to improve its market image and bolster investor confidence in its future growth potential, particularly in light of its commitment to developing novel psychedelic treatment solutions.
- Strategic Development Focus: Clearmind is currently focused on developing neuroplastic drugs targeting under-treated health issues and will continue to seek patent protection to enhance its intellectual property portfolio, further strengthening its competitiveness in the biotech sector.
Continue Reading
Clearmind Regains Nasdaq Compliance with Share Price Above $1
- Compliance Regained: Clearmind Medicine received confirmation from Nasdaq on December 30, 2025, that its share price exceeded $1 for the last 10 consecutive trading days, thereby regaining compliance with Nasdaq Listing Rule 5550(a)(2) and resolving previous compliance issues.
- Price Fluctuation Context: The company was notified on December 4, 2025, of non-compliance due to its common shares closing below $1 for over 30 consecutive trading days, highlighting market concerns regarding its stock price volatility.
- Future Growth Potential: Clearmind focuses on developing novel neuroplastogen-derived therapeutics, particularly for alcohol use disorder, which is expected to attract more investor interest in its innovative treatment solutions, further stabilizing and potentially increasing the company's stock price.
- Intellectual Property Strategy: The company currently holds 19 patent families and 31 granted patents, with plans to seek additional patents to enhance its market competitiveness, demonstrating a long-term strategic vision in the biotechnology sector.
Continue Reading